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Influence of Dietary Fats and Relation to Arterial Thrombus
Formation in Rats
G. Hornstra and H.C. Hemkerl
Unilevei Research Vlaardingen, and Department of Biochemistry, Biomedical Centre,
State University of Limburg, Maastricht
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Abstract. A small piece of vascular tissue punched from a rat aorta is able to clot
plasma. This coagulation plocess is promoted by blood platelets, especially after their
activation. Thrombin, generated by this clotting process, plays a key role in vessel-wall
induced platelet activation. Vascular prostacyclin inhibits vessel-wall-induced clotting of
platelet-rich plasma, possibly by inhibiting platelet activation. Type and amount of dietary
fats were shown to influence vessel-wall-induced clotting via at least four different mecha-
nisms, namely: by modifying vascular prostacyclin formation; by affecting the clotting
potency of the vascular tissue per sec; by an effect on some platelet property, probably
connected with platelet activation; by influencing a plasma factor.
Each of these mechanisms, as well as the nature of vessel-wall-induced coagulation,
requires further investigation.
lntroduction
When investigating dietary influences on vascular prostacyclin formation, we
noticed that a piece of tissue punch€d from a rat or rabbit aorta is able to clot
platelet-rich plasma (PRP). Since this coagulation process may be important in
arterial thrombus formation, we decided to investigate it in more detail.
1 We wish to thank Messrs. E Haddeman and l.A. Don for measurinq arterial throm-
bosis tendency and platelet MDA formation.
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Materials and Methods
V es sel- llall-Induced Clo tting
Rats are bled under ether anaesthesia by puncturing the abdominal aorta. The blood is
collected in citrate; PRP and platelet-poor plasma (PPP) are prepared by differential
centrifugation. The aortas are rapidly removed, cleaned from adhering tissue, opened
longitudinally and kept in an ice-cold Krebs-Henseleit buffer (KH). sGpl PRP or PPP and
450-pl Ca*t-containing saline (0.5 X 10-6 mol 1-1 CaCl, in 0. 154 moll-1 NaCl) are placed
into the cuvette of an aggregometer. The temperature is maintained at 37.5 eC and the
stirring speed is 600-700 rev/min. After 3 min, a small piece of tissue, diameter 3 mm, is
punched out of the aorta, transfeffed into the cuvette while light transmission is recorded
continuously. Clotting is indicated by a sudden change in light transmission (fig. l),
following the well-known picture of platelet aggregation, if present. The time lapse between
tissue addition and the moment of clotting is called the clotting time, tg, which for
statistical reasons, is indicated by the clotting index: S = l/tc X 1,000. S is higher, the higher
the clotting tendency of the plasma. Initially, measurements were discontinued after a
clotting time of 1,200 sec had been reached. The S-value of these measurements was taken
as 0.83. In later experiments, the Ca**-content of the saline was increased to 0,65 X 10-6
mol 1- r, which prevented the occurrence of these long clotting times.
Vascular Prostacyclin Production in Autologous PRP
A piece of vascular tissue, pretreated or not with indomethacin (2 pE ml-' for at least
th), is added to a 1:10 dilution of PRP in Ca"acontaining saline in the aggregometer.
30 sec later, adenosine diphosphate (ADP) is added to a final concentration of 0.25 x 10-6
mol 1-t; the resulting aggregation is quantified by measuring the tangent to the steepest
part of the aggregation slope (V). Due to prostacyclin (PGI,) production, aggregation in the
presence of normal vascular tissue is lower than that on addition of a piece of indometha-
cin-treated aorta. Therefore, the proportional difference in aggregation, induced by ADP in
the presence of either a piece of normal aorta or a piece of indomethacin-treated tissue, is
taken as a measure of the amount of PGI2 formed.
This technique for measuring vascular PGI, production is used to include all possible
influences due to such physiological factors as plasma prostacyclin inhibitors/stimulators
(11, 16, 19, 22,23,26) andlor possible differences in platelet prostacyclin sensitivity which
are not observed when PGI, production occurs in buffer and PGI, measurements are
performed by chemical means or by using an indifferent PRP.
Arterial Thrombosis Tendency in viv o
Arterial thrombosis tendency is determined by measuring the obstruction time (OT) of
a loop-shaped, polyethylene canula inserted into the abdominal aorta (9).
Platelet Arachidonate Percxidation
Platelet arachidonate peroxidation upon triggering with a supramaximal dose of col-
lagen is measured by formation of malondialdehyde (MDA) as described by Smith et
al. (25).
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Fig. 1. Clotting-induced changes in light transmission (AT, %) in PPP (A) and PRP,
preceded (C), or not (B), by platelet aggregation. 'Spikes' are caused by the tissue when
passing the light beam; a = aorta; ai = aorta, pretreated with indomethacin.
Fig. 2. Effect of the presence of platelets on vessel-wall-induced clotting. Figures below
bars represent clotting times (s) calculated from mean S-values; n = 28; mean t SEM.
Results and Discussion
Effect oJ Blood Platelets on Vessel-llall-Induced Clotting
To establish whether the presence of platelets is a prerequisite for vessel-
wall-induced coagulation, clotting times were determined upon incubation of
aortic tissue in PRP and PPP, respectively. Clotting occurred in both media;
however, in PRP it was significantly enhanced (p, ( 0.01) as compared with PPP
(fie. 2).
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Fig. 3. Effect of arachidonic acid deficiency onvessel-wall-induced lotting (S, mean t
SEM). (A) = Non-treated aorta in autologous PRP (n = 10); (B) = Indomethacin-treated
aorta in autologous PRP (n = 12); (C) Arachidonic-acid-deficient a d control aortas in
teference PPP (n = 7); (D) Reference aorta in arachidonic-acid-deficient andcontrol PPP (n
= 12). Figures below bars represent clotting times (s) calculated from mean S-values.
The aggregometer tracings of PRP did not show platelet shape change and
aggregation, indicating that for this pro-coagulant activity, platelets not in direct
contact with the vessel wall need not be activated. However, it remains possible
that the adhered and thereby activated platelets are responsible for the clot-
promoting effect observed.
Effect of Vascular hostacyclin on Vessel-l,lall-Induced Clotting
Although the injured vessel wall provides a thrombogenic surface, prosta-
cyclin produced by the vascular tissue prevents activation of the non-adhering
platelets. When prostacyclin formation is blocked, vessel-wall-induced clotting is
always preceded by platelet shape change and aggregation. (fig. lC). Two experi-
ments were performed to investigate whether lowering of prostacyclin formation
affects vessel-wall-induced clotting of PRP.
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Fig. 4. Effect of dietary fat on vessel-wall-induced clotting (S, mean r SEM) in Wistar
rats. (A) Non-treated aortas in autologous PRP (n = 9); (B) Indomethacin-treated aortas in
autologous PRP (n = 9); (C) Aortas in standard PPP (1 = 10); (D) Standard aorta in different
PPPs (n = 7). Figures below bars represent clotting times (s) calculated from mean S-values.
Effect of Drugs Inhibiting PGI2 Synthesis
Vascular tissue was pre-incubated in KH buffer containing indomethacin
(2 ttg nl-'), aspirin (100 pe ml-1) or tranylcypromine (500 prg ml-1). These
treatrnents greatly diminished vascular prostacyclin production, caused platelet
shape change and aggregation and enhanced vessel-wall-induced clotting in PRP
(for indomethacin: see figs. 3 and 4). This indicates that prostacyclin may
regulate vessel-wall-induced clotting possibly by inhibiting platelet activation.
However, a direct effect of these drugs on vessel-wall-induced clotting cannot be
excluded.
Effect of Arachidonic Acid Deficiency
Aortas of arachidonic-acid (AA)-deficient animals produce only small
amounts of PGI2 (7). So, if prostacyclin plays a regulating role in vessel-wall-
induced clotting, this process might be expected to be enhanced in AA defi-
ciency. Two groups of rats were used for the experiment: one group received a
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Table l. Arterial thrombosis tendency (OT) and vascular production ofplatelet aqgregation
inhibiting substance (AV) by rats fed different diets (mean t SEM)
Dietr Strain'? OT (n = 16)
log h
2I6
AV
5 en% SO
5 en%HCO3
50 en% SO
40 en%HCO"
50 en%LO
50 en% SO
50 enVo CBa
50 en%CLOa
w
w
1.99 t 0.054
2.29 t 0.049
2.27 + 0.041
1.99 t 0.037
2.21 ! 0.054
5
5
5
97
195
187
98
163
T2
t )
1 0
1 1
l 1
8
8
8
79.7 t 3.77
21.9 x 4.L9
67.6  +  5 .82
76.6 t 3.48
23.6 ! 5.64
51.5  t  4 .09o
54.5  t  3 .166
4L.9 ! 3.776
w
w
w
FH
FH
FH
t SO = Sunflower-seed oil; HCO = hardened coconut oil; LO = linseed oil; CB = cocoa
butter: CLO = cod-liver oil.
'? W = Wistar rats; FH = Fawn Hooded rats.
3 Arachidonic acid deficient.
a Dietary fat 45 en%;5 enVo SO added to prevent arachidonic acid deficiency.
s No reliable value. because ctrca 50% of the animals were lost due to bleeding problems or
embolization of the arterial thrombus.
6 Slightly different measuring procedure, leading to lower values. In fact, PGlr-production
in FH rats is significantly higher than in W rats.
diet containing 5 energy Vo (enTo) sunflower-seed oil (control group) whereas the
other group was fed a comparable diet with hardened coconut oil. This diet
contains no linoleic acid, as a result of which it causes AA deficiency after a
feeding period of about 3 months. Two series of clotting measurements were
performed: one with a piece of normal, non-treated aorta and one with a piece
of the same aorta, pretreated with indomethacin (2pg ml-l) for at least I h.
Moreover, vascular prostacyclin production was measured, which confirmed the
low PGl2-producing potency of AA-deficient aortas (table I). In the first series
of coagulation studies, clotting induced by AA-deficient aortas in autologous
PRP, appeared to be significantly (p = 0.01) enhanced compared to that
occurring with control material (fig. 3A). In the AA-deficient group, clotting was
preceded by platelet shape change and aggregation. In the second series, indG
methacin-treated aortas were used, thereby preventing.any effect of vascular
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prostacyclin. Compared to non-treated tissue, an increased clotting response was
observed in both groups. Moreover, the difference between the two groups was
greatly diminished after indomethacin treatment (fig. 3B). These observations
strongly suggest that blood platelets enhance, especially after activation, the
clotting response induced by damaged vascular tissue and that prostacyclin
produced by the vascular wall, inhibits this clotting response by inhibiting
platelet activation.
However. the residual difference in clotting between both groups after
prostacyclin blocking suggests that prostacyclin-independent factor(s) may af-
fect vessel-wall-induced coagulation as well. This suggestion is supported by the
observation (fig. 3C) that clotting induced by AA-deficient vascular tissue in an
indifferent standard PPP, is still significantly b < 0.05) enhanced over that
induced by pieces of control aortas. Therefore, it is likely that AA-deficient
aortas possess an increased clotting potency per se. No clotting difference was
observed when pieces of standard aolta were incubated in PPP from AA-defi-
cient or control animals (fig. 3D)'
Effect of Type of Dietary Fat on Vessel'lrlall'Induced Clotting
To investigate whether the clotting response upon PRP-vessel wall interac-
tion is influenced by the type of dietary fat, and if any dietary fat effect is
mediated through the platelet release reaction, two sets of experiments were
carried out: one in normal Wistar rats and one with release-deficient Fawn-
Hooded rats.
Normal llistar Rats. Three groups of rats were fed diets in which 5vo of the
energy was provided by either sunflower-seed oil (So, mainly linoleic acid)
linseed oil (Lo, mainly linolenic acid) or hardened coconut oil (HCO, mainly
saturated fatty acids). After 3 months, the arterial thrombosis tendency was
determined irf one half of the animals. In the other animals, the aortic wall-
induced clotting in autologous PRP was measured, as were vascular prostacyclin
production and platelet arachidonate peroxidation.
The results confirmed the differences in arterial thrombosis tendency and
prostacyclin production (table t) found on earlier occasions (6). They also
indicated clear differences in the mean clotting response of each group, the
saturated fat group showing the highest and the linoleic acid-rich group, the
lowest clotting tendency (fig. aA). Due to wide individual variations, the differ-
ences did not reach the level of statistical significance. However, a striking
relationship was observed between arterial thrombosis tendency and vessel-wall-
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Fig. 5. Relationship between vesselwall-induced clotting in autologous PRP (S t SEM)
and arterial thrombosis tendency (log OT I SEM) measuted in different groups of animals
receiving 50 enVo fat-containing diets. SO = sunflower-seed oil; LO = linseed oil; HCO =
hardened coconut oil.
induced clotting (fig. 5), which indicates that this clotting response may contrib-
ute to arterial thrombus formation. When prostacyclin action is prevented by
using indomethacin-treated aortas, coagulation in autologous PRP is enhanced in
all three groups (fig. aB). In the LO group, this enhancement is very small,
leading to a significantly (p < 0.05) lower clotting tendency than in the other
groups. Since no clotting differences were observed upon incubation of non-
treated aortas in standard PPP (fig. 4C) or upon incubation of pieces of standard
aorta in the different PPPs (fig. 4D), this must be due to a low 'activation grade'
of the LO platelets induced by the vessel wall which can be either platelet- or
aorta-bound. Most probably, the low 'activation grade' is caused by some
platelet property, since arachidonate peroxidation upon supramaximal triggering
with collagen appeared to be significantly lower than in the other groups (MDA
formafion in 10-e mol per lOe platelets; LO: 0.78 10.055; SO: 1.27 t 0.118;
HCO: 1.44 t 0.080; n= l2,mean t SEM).
Fawn-Hooded Rats. Fawn-Hooded (FH) rats have a hereditary defect of the
platelet-release reaction: their dense granules, which, in normal animals, contain
ATP, ADP, Ca**, serotonin, pyrophosphate and antiplasmin (5), seem to be
empty, leading to reduced platelet nucleotide and serotonin contents (21,27).
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Fig. 6. Effect of type of dietary fat on vessel-wall-induced clotting (S t SEM) in
Fawn-Hooded rats (n = 8). (A) Aortas in autologous PRP; (B) Aortas in PRP of standard FH
rats; (C) Standard FH aorta in different PRPs; (D) Standard FH aorta in different PPPs.
Figures below bars represent clotting times (s) calculated from mean S-values.
This defect is thought to be the underlying mechanism of the bleeding tendency
observed in these animals (27).
Three groups of FH rats were fed 50 en% fat-containing diets. SO was used
as a linoleic acid-rich control, cocoa butter (CB) as a highly saturated fat and
cod-liver oil (CLO) as a typical long-chain polyunsaturated oil. After 3 months'
feeding, aortic-wall-induced clotting of PRP was measured, as was PGI2 produc-
tion by these aortas. In these 'release deficient' animals, vessel-wall-induced
clotting of PRP is not enhanced by saturated fat feeding (fig. 6A) as was
suggested to be the case in normal rats (fig. 4A). This discrepancy needs further
investigation.
The very low clotting response in the CLO group (fig. 6A,) cannot be due to
vascular prostacyclin, because the total production of aggregation-inhibiting
substances by the aortas of this group is lower than that in the other groups
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Tablel l .Effectof aspir intreatmentof PRP(0.55 x 10-3mol 1- ')onplateletaggregation
induced by a piece (4 3 mm) of damaged vessel wall (indomethacin-treated), collagen (5.6 X
10-6 g protein ml-r final concentration), ADP (0.25 X 10-6 mol ml-r f.c.) and thrombin
(0.09 U ml-r, f.c.) in Wistar (W) and Fawn Hooded (FH) rats
Vessel wall
(aT, n = 21)
Collagen
(AV, n = 7)
ADP
(AT, n = 7)
Thrombin
(aT, n = 7)
w
W + aspirin
Difference
P2
FH
FH + aspirin
Difference
P2
4 2 . 8  !  3 . 1 2
39.4 ! 2.68
-3.5 ! 2.74
> 0 .10
l l . 0  1  1 . 8 1
12.6 ! 2.46
+ 1.6 r 1.66
> 0 . 1 0
3.04 1 0.30
0.94 ! 0.29
- 2 . 1 0  x  0 . 3 2
<0.001
0.08  i  0 .018
0
-0 .08  1  0 .018
<0.005
34.2 ! 2.81
28.0 x 3.21
-6 .3  +  1 .70
0.01
32.8 ! 2.72
26.9 t 2.88
*5 .8  r  1 .30
<0.005
48.5 t 2.42
49.3 x 2.68
+ 0 .8  !  2 .72
> 0 . 1 0
18.8  i  1 .87
16.7 t 2.54
-2 .1  x  2 .66
> 0 . 1 0
(table I). Moreover, it is not caused by another vascular factor because aortas of
the three groups, incubated in PRP of standard FH rats showed essentially
similar clotting potencies (fig. 68). However, when pieces of standard aorta were
incubated with different PRPs (fie. 6C) or PPPs (fig. 6D), clotting was always
lowest in the clo plasma, both other groups showing no difference at all.
Therefore, it is very likely that the lower vessel-wall-induced clotting of PRP
caused by CLO feeding can be ascribed to a plasma factor.
Vessel-Wall-Induced Platelet Reactions: Role of Thromboxane Azand ADP
Clotting of PRP, brought about by a piece of vascular tissue producing little
or no prostacyclin, is preceded by platelet shape change and aggregation
(fig. 1C). The time course of these platelet reactions very much resembles that of
collagen-induced aggregation, which is mediated by Thromboxane A2 (TxA2,
24) produced by and ADP released from platelets that adhered to the collagert.
This suggests that the vessel-wall-induced platelet reactions are mediated by the
same processes. However, pre-incubation of PRP with aspirin (0.55 X 10-3 mol
l-1) for I h did not significantly reduce the vascular-tissue-induced platelet
reactions, whereas ADP- and collagen-induced agSregation of PRP was signifi-
cantly inhibited by this aspirin treatment (tabte n). Therefore, neither TxA2 nor
ADP seems to play a primary role in this type of platelet-vessel-wallinteraction
in vitro.
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Table lll. Effect of hirudin on platelet function and clotting of PRP, induced by indo-
methacin-treated vascular tissue (n = 5; mean t SEM)
Hirudin dose
(x  10- '?  ATUmI- t f . c .
Shape change Aggregation Coagulation
(^T' %) (^T, Vo) (S)
0
3.125
6.25
t2.5
25
50
5 . 8  1  1 . 3 9
4.6 t 0.56
6.0  t  1 .55
3.4 t 0.90
3.8  t  1 .04
2.0  x  0 .23
19.0 ! 2.37
1.6  t  1 .03
3.2  !  3 .0L
0
0
0
6.28 x 0.284
4.89 t 0.442
4.53 t 0.603
3.31  t  0 .480
1.43  I  0 .333
1.06 t 0.254
However, the damaged vessel wall may be a strong enough trigger to induce
ADP release independent of platelet arachidonate peroxidation (3, 33). There-
fore, the role of ADP was further investigated by using the ADP dephosphorylat-
ing enzyme apyrase (1) and the ADP transphosphorylating system creatine
phosphate/creatine phosphokinase (10). These ADP scavengers inhibited platelet
aggregation, only in doses about two times higher than those needed to block a
comparable degree of aggregation induced by added ADP.
Vessel-Wall-I nduced Platelet Reactions : Ro le of Thrombin
Since the PRP-vessel-wall interaction triggers a clotting lesponse, the preced-
ing platelet reactions may be caused by thrombin. we tested this hypothesis by
using hirudin, a potent and specific thrombin-inactivating polypeptide which
does not modify ADP-induced aggregation. This substance very effectively
blocks platelet aggregation when added to PRP in doses only slightly effective in
lowering the clotting response. Hirudin appeared a less efficient inhibitor of
platelet shape change (table III). As shown before (table II), the platelet re'
sponse brought about by damaged vascular tissue is not inhibited by aspirin. The
same aspirin treatment is equally ineffective in modifying thrombin-induced
aggregation. Moreover, in PRP of FH rats, vessel-wall-induced platelet reactions
are significantly less pronounced than in Wistar rats. The same holds for
thrombin- but not for ADP- and collagen-induced aggregation (table II)'
These striking similarities between vessel wall induced and thrombin-
induced aggregation, together with the efficient inhibition by the anti-thrombin
agent hirudin of aggregation induced by the damaged vascular wall, strongly
suggests that this aggregation is mediated by thrombin, generated as a result of
Hornstra/Hemker
vessel-wall-induced clotting. Since ADP scavengers had also some inhibitory
effect on vessel-wall-induced platelet reactions, a supporting role of ADP re-
leased from adherent platelets and/or from non-adherent platelets, activated by
the generated tfuombin, cannot be excluded. In this respect, it seems relevant
that the effective doses of these ADP-removing systems also inhibit thrombin-
induced aggregation.
General Discussion
We demonstrated that injured vessel wall is able to clot plasma. It has not
yet been established whether this process is of intrinsic or extrinsic origin. Since
vessel wall preparations have a high tissue factor activity (for review, see ref. 17),
extrinsic clotting seems the most likely process. However, preliminary experi-
Fig, 7. Diagram to illustrate processes possibly involved in thrombus formation follow-
ing vascular injury. For explanation: see text.
\-
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ments with factor-Vll-deficient plasma were inconclusive, which might have
been due to the perforce use of heterologous plasma in this type of experiment.
The intrinsic pathway of coagulation may also be involved in vessel-wall-
induced clotting, since subendothelial collagen is able to activate factor XII (18,
32). Moreover, platelets which have been shown to enable the initiation (28,29)
and the stimulation (30, 3l) of the intrinsic pathway, clearly stimulated vessel-
wall-induced clotting (fi9.2). This effect did not require massive activation of
the available platelets, as wits demonstrated by the absence of platelet shape
change and aggregation. This observation, together with recent findings (not
shown) that aspirin treatment of PRP does not modify vessel-wall-induced
clotting of this PRP, makes it rather unlikely that the enhancing effect of
(activated) blood platelets on coagulation induced by vascular tissue is due to
platelet factor 3 activity (4, 3l).
If we consider our findings in the light of literature data, the following
picture emerges as to the processes resulting from the interactions between
damaged vessel wall and blood constituents $g.7). In the first reaction phase,
the endothelial injury causes the adhesion of blood platelets to subendothelial
structures, followed by the activation of the adhered platelets. Tissue factor
activity of the injured blood vessel triggers the extrinsic pathway of coagulation,
leading to the formation of activated factor X in close proximity to adhered
blood platelets. These platelets, following activation, have disclosed specific
receptors for activated factor X, as a result of which Xu binds to their surface (2,
12, I3). There is substantial evidence that activated factor V acts as this receptor
(14, 2O). Together with platelet membrane phospholipids and Ca"*, V" accel-
erates the X"-mediated proteolysis of prothrombin to thrombin at the platelet
surface. Although, initially, the amount of thrombin generated in this way is
only very small, the local concentration will be sufficient to uncover Xu
receptors on fresh platelets. These have, in the meantime, concentrated around
the vascular injury due to the aggregating activity of TxA2 produced by, and
ADP released from, the adhered platelets. This enables X" to produce more
thrombin. By activating factor VIII, thrombin may promote its own formation
via the intrinsic clotting pathway (17), which is also initiated by the injured
vessel wall. Via these positive feedback mechanisms, the local thrombin concen-
tration is boosted. Since thrombin is a very potent platelet aggregating and
releasing agent, it cooperates with TxA2 and ADP in the production of a 'white
platelet tlrombus', the growth of which will be counteracted by prostacyclin
generated in the vessel wall (15) from endogenous precursors (8, 34). The white
thrombus has a fragile structure and embolizes very easily. However, thrombin
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also mediates the formation of fibrin which consolidates the fragile platelet mass
to a stable arterial thrombus of great pathological significance.
For a long time, the participation of coagulation in arterial thrombogenesis
has been considered to be of secondary importance. However, it is now gradually
becoming clear that white thrombus formation and blood clotting are two
intimately linked processes equally important in arterial thrombogenesis. The
effect of dietary fats on various platelet functions and on the presently described
clotting response, induced by damaged vascular tissue, may be the basis of their
influence on arterial thrombosis and atherosclerosis in animals and man.
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